Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a research report report published on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $5.00 price objective on the stock.

Several other brokerages also recently issued reports on HOTH. Wall Street Zen downgraded shares of Hoth Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Hoth Therapeutics in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Hoth Therapeutics has an average rating of “Hold” and a consensus target price of $5.00.

Hoth Therapeutics Price Performance

Shares of Hoth Therapeutics stock opened at $0.99 on Wednesday. The firm’s fifty day simple moving average is $1.00 and its 200-day simple moving average is $1.23. Hoth Therapeutics has a 12 month low of $0.66 and a 12 month high of $2.12. The stock has a market capitalization of $15.40 million, a price-to-earnings ratio of -0.94 and a beta of 0.50.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC purchased a new stake in Hoth Therapeutics in the 3rd quarter valued at approximately $232,000. Geode Capital Management LLC raised its stake in shares of Hoth Therapeutics by 18.0% during the 4th quarter. Geode Capital Management LLC now owns 181,112 shares of the company’s stock worth $179,000 after buying an additional 27,577 shares in the last quarter. DRW Securities LLC purchased a new position in shares of Hoth Therapeutics during the 4th quarter worth approximately $257,000. Virtu Financial LLC acquired a new stake in shares of Hoth Therapeutics in the 3rd quarter valued at approximately $184,000. Finally, Kestra Private Wealth Services LLC acquired a new stake in shares of Hoth Therapeutics in the 3rd quarter valued at approximately $51,000. 7.08% of the stock is owned by hedge funds and other institutional investors.

About Hoth Therapeutics

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.